Placeholder canvas

January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

Feb 10, 2022 | Deal of the Month, Partnership Deals

January 2022 Top Biopharma Deal Upfront
Beam research partnership with Pfizer with a license option for up to three therapies for rare genetic diseases

Highlighted Deal Financial Comps

Date Announced:

January 10, 2022

Total Deal Value:


Upfront Cash:


Upfront Equity:


Option Payments:


Total Milestones:

up to $1,050M (dev., reg., and sales)


Undisclosed, per program

Cost & Profit Split:

65%/35% (Pfizer/Beam) if co-dev and co-pro option is exercised

Deal Synopsis

The Asset:

Beam’s proprietary in vivo base editing and LNP delivery technologies for the treatment of rare genetic diseases of the liver, muscle, and CNS

Deal Structure:

Option to License

Partnership Features:

Option to Co-Develop and Co-Promote with Shared Costs

Deal Details:

  • Beam signed a three year research partnership with Pfizer to co-develop in vivo base editing programs against three targets using its in vivo base editing and delivery technologies for the treatment of rare genetic diseases of the liver, muscle, and central nervous system with an exclusive, worldwide option to license each program.
  • Beam may opt-in to global co-development and co-promotion for one licensed program; exercisable at the end of Phase 1/2 by paying an option exercise fee.
  • Beam will receive $300M up front and is eligible to receive up to $1.05B in development, regulatory, and sales milestones, plus royalties per licensed program if not opted for co-development / co-promotion.
  • If Beam opts in to co-dev/co-pro, both companies will share cost and profits 65%/35% (Pfizer/Beam).

Last Month:

Congrats to Beam and Pfizer for landing DealForma’s January 2022 Top Biopharma Deal. Last month’s Deal of the Month was Foghorn – Loxo using Gene Traffic Control for new oncology treatments. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...